24-h Efficacy of Glaucoma Treatment Options

被引:0
|
作者
Anastasios G. P. Konstas
Luciano Quaranta
Banu Bozkurt
Andreas Katsanos
Julian Garcia-Feijoo
Luca Rossetti
Tarek Shaarawy
Norbert Pfeiffer
Stefano Miglior
机构
[1] Aristotle University of Thessaloniki,1st University Department of Ophthalmology
[2] Aristotle University of Thessaloniki,3rd University Department of Ophthalmology
[3] University of Brescia,Glaucoma Unit
[4] Selcuk University,Department of Ophthalmology
[5] University of Ioannina,Department of Ophthalmology
[6] University of Madrid,Eye Clinic, San Paolo Hospital
[7] University of Milan,Glaucoma Sector
[8] University of Geneva,Department of Ophthalmology
[9] University of Mainz,undefined
[10] University Bicocca of Milan,undefined
来源
Advances in Therapy | 2016年 / 33卷
关键词
24-h efficacy; 24-h intraocular pressure control; Circadian intraocular pressure characteristics; Diurnal intraocular pressure; Glaucoma therapy options; Intraocular pressure monitoring; Ophthalmology;
D O I
暂无
中图分类号
学科分类号
摘要
Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis.
引用
收藏
页码:481 / 517
页数:36
相关论文
共 50 条
  • [41] Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview
    Andreas Katsanos
    Nikoleta Tsaldari
    Konstantina Gorgoli
    Fotios Lalos
    Maria Stefaniotou
    Ioannis Asproudis
    Advances in Therapy, 2020, 37 : 1319 - 1327
  • [42] Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
    Kazuhide Kawase
    Jason L. Vittitow
    Robert N. Weinreb
    Makoto Araie
    Advances in Therapy, 2016, 33 : 1612 - 1627
  • [43] Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
    Kawase, Kazuhide
    Vittitow, Jason L.
    Weinreb, Robert N.
    Araie, Makoto
    ADVANCES IN THERAPY, 2016, 33 (09) : 1612 - 1627
  • [44] A retrospective analysis of long-term outcomes following a single episode of transscleral cyclodiode laser treatment in patients with glaucoma
    Zhekov, Ivailo
    Janjua, Razia
    Shahid, Humma
    Sarkies, Nicholas
    Martin, Keith R.
    White, Andrew J. R.
    BMJ OPEN, 2013, 3 (07):
  • [45] Towards Precision Ophthalmology: The Role of 3D Printing and Bioprinting in Oculoplastic Surgery, Retinal, Corneal, and Glaucoma Treatment
    Wu, Kevin Y.
    Tabari, Adrian
    Mazerolle, Eric
    Tran, Simon D.
    BIOMIMETICS, 2024, 9 (03)
  • [46] 2nd Special Issue: Tackling key immunological and immuno-dermatological pathways and their link to treatment options
    Boda, Daniel
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (03) : 2339 - 2343
  • [47] Comparisons of the short-term effectiveness and safety of surgical treatment for neovascular glaucoma: a systematic review and network meta-analysis
    Lin, Peijie
    Zhao, Qian
    He, Jing
    Fan, Wei
    He, Wenyi
    Lai, Mingying
    BMJ OPEN, 2022, 12 (05):
  • [48] Topical dilation as first-line treatment for fibrin membrane pupillary-block glaucoma following uncomplicated cataract surgery
    Bennett, Sashia
    Studsgaard, Anne
    Telinius, Niklas
    BMJ CASE REPORTS, 2023, 16 (04)
  • [49] 24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost
    Konstas, Anastasios G. P.
    Voudouragkaki, Irini C.
    Boboridis, Kostantinos G.
    Haidich, Anna-Bettina
    Paschalinou, Eleni
    Giannopoulos, Theodoros
    Dragoumis, Nikolaos D.
    Makridis, Alexandros K.
    Kahook, Malik Y.
    ADVANCES IN THERAPY, 2014, 31 (06) : 592 - 603
  • [50] 24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost
    Anastasios G. P. Konstas
    Irini C. Voudouragkaki
    Kostantinos G. Boboridis
    Anna-Bettina Haidich
    Eleni Paschalinou
    Theodoros Giannopoulos
    Nikolaos D. Dragoumis
    Alexandros K. Makridis
    Malik Y. Kahook
    Advances in Therapy, 2014, 31 : 592 - 603